Introduction
Vaccine therapy with tumor (cancer)-associated antigens or tumor-derived heat shock protein is a promising development in the field of tumor immunotherapy. The majority of the clinical trials were/ are either aimed at the generation of a tumor-specific cytolytic T lymphocyte (CTL) response in the patients or injecting the patients with ex vivo expanded tumor antigen-specific CTL. Following vaccine therapy or CTL infusion, several studies have documented tumorspecific CTL in patients' blood at the vaccine site and also at distant (regressing) tumor sites. Dramatic clinical antitumor responses have even been seen in advanced cancer following this type of immunotherapy. The major problem with this approach is that the in vivo expansion of antigen-specific CTL is neither persistent nor robust. and combinations. [3, 4] In human tumors, IL-10 was found to be the most important tumor.
Innate and adaptive immunity and immune homeostasis
The innate immune system consists of a diverse to the need or i-Tregs. [3, 4] The homeostasis is achieved by the regulatory T lymphocytes. Figure 2A Immunosuppression by IL-10 producing Treg or Tr1 type of cells. IL-10 is a cytokine that shows potent immunosuppressive and anti-inflammatory activity. [9] It has the ability to inhibit the production of pro-inflammatory cytokines, such as tumor necrosis factor-α, IL-1, IL-6, and IL-12 as well as IL-2 and interferon (IFN)-γ. The important role of IL-10 in controlling inflammation is exemplified by IL-10-/-mice, which develop inflammatory bowel disease. [10] [11] [12] [13] [14] [15] [16] Multiple studies have shown the roles of IL-10 in suppressing the immune response to infectious disease and suppressing the development of autoimmune disease. Altogether, the role of IL-10 appears to be to limit the effect of pro-inflammatory cells and the cytokines they produce to prevent damage to the host and to maintain self-tolerance.
Initially, IL-10 was described as a product of the Th2 type of cells. Subsequent work has shown that IL-10 is produced by multiple cell types, including Th1 cells, Tr1 cells, NKT cells, B cells, macrophages, keratinocytes, and carcinoma cell lines. [10] [11] [12] [13] [14] [15] Despite the fact that various types of cells can produce IL-10, little is known about the control of IL-10 transcription and gene expression. It is known that IL-10 expression is controlled at both the transcriptional and the post transcriptional levels. [14] [15] [16] Two separate studies have shown that the only essential element of the mouse IL-10 promoter is a single Sp1/ Sp3 site. [16] Because Sp1/Sp3 proteins are ubiquitous, the mechanism controlling IL-10 expression in different cell types is not clear. Moreover, it is not clear whether a single Sp1/Sp3 site in theIL-10 promoter is sufficient for driving high-level IL-10 expression in Th2 cells.
Control of the immune response via circulating 5′ adenosine monophosphate (AMP) and the adenosine pathway
A subpopulation of peripheral blood lymphocytes (PBL) expresses CD73. [16] CD73/ecto-5nucleotidase patients. [22, 23] Fludarabine has a binding affinity for CD73
expressed by certain CD4+ cells and those are termed as uncommitted prime precursors with a potential to be effective suppressors of the inflammatory responses. [20] Presence of fludarabine in low dose in culturemaintained functional CTLs generated in cultures with total PBL Several studies, preclinical or clinical, have shown that the CTL responses induced by vaccine therapy in patients or in vitro in stimulation cultures are short lived. [24] [25] [26] We have also shown in in vitro cultures that the induction of CD8+ CTL responses decline in mixed culture with total PBL whereas CTL responses in culture with purified CD8+ cells remain significantly longer in cultures. [25] Table 1 summarizes the results of in vitro cocultures to induce tumor antigen-specific CTL response using total PBL and purified CD8+ cells.
We have studied the effect of the drug fludarabine at a very low dose (10 ng/ml) in cultures with PBL from patients and normal donors. Phenotypic and functional activity of the expanded CTL in cultures was analyzed. [26] The cultures were fed every other day with appropriate cytokine and with and without the drug and were restimulated with appropriate stimuli every 7-10 days.
Culture conditions and cytokine doses are described in previously published articles. [25] [26] [27] The cytokine secretion and cytolytic activity assays with the responding CTLs from the cultures were carried out after 14 and 28
days from the initiation of the cultures. The statistical comparison of the data was performed within the different conditions of the cultures with PBL and these were then Chakraborty: IL-10 and immunotherapy of cancer enzyme-linked immunosorbent assay for IFN-γ and IL-10 were performed. Table 2 represents the data with PBL only and with PBL, where the drug fludarabine was present continuously. It is clear that the presence of fludarabine generated better antigen-specific cytokine-producing cells when compared with control PBL IVC. In some of the control PBL IVCs, the IFN-γ-producing ability was totally lost and the difference found using the different culture conditions was found to be very significant (P < 0.05).
The expanded antigen-specific cells in the cultures with fludarabine continued to be functional for a longer period as compared with control PBL cultures in an autologous-DC-based restimulation system. [29] We have also observed
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Conclusion

Animal model experiments have established the
Chakraborty: IL-10 and immunotherapy of cancer further compared with in vitro cocultures (IVCS) with CD8+ cells, as described. [27] [28] [29] The following [ Tables 2 and   3 ] represent the data of IFN-γ response and cytotoxicity assays, respectively, with the expanded CTL populations. as previously described. [25] [26] [27] [28] After 24 h, the supernatants from the wells were collected and cytokine assays by 
